Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection

Conditions

• Melanoma
• Adjuvant

Interventions

• DRUG: Dabrafenib and Trametinib
• DRUG: Dabrafenib
• DRUG: Trametinib

Sponsor

Novartis Pharmaceuticals